Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer

Journal of Pathology

Volumn 191, Issue 1, 2000, Pages 39-47

  Ow, Kim ^a,b   Delprado, Warick ^c   Fisher, Richard ^a   Barrett, Julie ^a,b   Yu, Yan ^a   Jackson, Paul ^a,b   Russell, Pamela J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

Author keywords

Bladder; KAI1; Metastasis; p53; pRb; Tumour marker

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY;

ANTIGENS, CD; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; KANGAI-1 PROTEIN; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034099741     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200005)191:1<39::AID-PATH580>3.0.CO;2-K     Document Type: Article

References (36)

1. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11 p11.2. Science 1995; 268: 884-886.
2. Dong J-T. Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56: 4387-4390.
3. Ueda T, Ichikawa T, Tamaru J, et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996; 149: 1435-1440.
4. Yu Y, Yang J-L, Marcovic B, et al. Loss of KAI1 messenger RNA expression in both high grade and invasive bladder cancers. Clin Cancer Res 1997; 3: 1045-1049.
5. Yang XH, Welch DR, Phillips KK, Weissman BE, Wei LL. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett 1997; 119: 149-155.
6. Phillips KK, White AE, Hicks DJ, et al. Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein. Mol Carcinogen 1998; 21: 111-120.
7. Takaoka A, Hinoda Y, Satoh S, et al. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene 1998; 16: 1443-1453.
8. Yang J-L, Jackson P, Yu Y, et al. Loss of KAI expression is associated with invasion and metastasis in cell lines derived from human sporadic colon cancer (submitted).
9. Takaoka A, Hinoda A, Sato S, et al. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 1998; 89: 397-404.
10. Adachi M, Taki T, Ieki Y, Huang C-I, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996; 56: 1751-1755.
11. Higashiyama M, Kodama K, Yokouchi H. et al. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favourable prognostic factor an immunohistochemical analysis. Cancer 1998; 83: 466-474.
12. Guo X, Friess H. Graber HU, et al. KAI1 is up-regulated in early pancreatic cancer and decreased in the presence of metastasis. Cancer Res 1996; 56: 4876-4880.
13. Friess H, Guo X-Z, Berherat P, et al. Reduced KAI1 expression in pancreatic cancer is associated with lymph nodes and distant metastases. Int J Cancer 1998; 79: 349-355.
14. Guo XZ, Friess H, Maurer C, et al. KAI1 is unchanged in metastatic and nonmetastatic esophogeal and gastric cancer. Cancer Res 1998; 58: 753-758.
15. Hinoda Y, Adachi Y, Takaoka A. et al. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett 1998; 129: 229-234.
16. Wright MD, Tomlinson MG. The ins and outs of the transmemhrane 4 superfamily. Immunol Today 1994; 15: 588-594.
17. Huang CL, Taki T, Adachi M, et al. MRP-1/CD9 and KAI1/ CD82 expression in normal and various cancer tissues, Int J Oncol 1997; 11: 1045-1051.
18. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of anti-proliferalive antibody-1 and leu-13 antigen. J Immunol 1992; 149: 2841-2850.
19. Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1996; 1287: 67-71.
20. Murphy WM, Bcckwith JB, Farrow GM. Tumours of the Kidney, Bladder, and Related Urinary Structures. Atlas of Tumour Pathology, Series 3. Fascicle 11. Armed Forces Institute of Pathology: Washington, DC, 1994.
21. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol 1998; 22: 1435-1448.
22. Cordon-Cardo C, Scheinfeld J, Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 1997; 13: 319-327.
23. Dorkin TJ, Robson CN, Neal DE. The molecular pathology of urological malignancy. J Pathol 1997; 183: 380-387.
24. Ozen H. Bladder cancer. Curr Opin Oncol 1998; 10: 273-278.
25. Haupt Y, Maya R, Kazac A, Oren M. MDM-2 promotes rapid degradation of p53. Nature 1997; 387: 296-299.
26. Kubbutal MH, Jones SN, Vousden KH. Regulation of p53 stability by MDM-2. Nature 1997; 387: 299-303.
27. Marcovic B, Wu ZH, Chesterman CN, Chong BH. Quantitation of Fe γ RII mRNA in platelets and megakaryoblastic cell lines by a new method of in situ hybridization. J Immunol Methods 1994; 72: 105-114.
28. Erba HP, Gunning P, Kedes L. Nucleotide sequence of the human γ cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes. Nucleic Acids Res 1986; 14: 5275-5294.
29. Ow KT, Mameghan H, Lochhead AH, et al. The prognostic significance of tumour-associated markers p53. HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localized human prostatic adenocarcinoma. Urol Oncol 1995; 1: 144-152.
30. Ribeiro JCC, Barnetson AR, Fisher R, Mameghan H, Russell PJ. Radiosensitivity is independent of p53 status in three human bladder cancer cell lines. Im J Radial Biol 1997; 72: 11-20.
31. Morton RA Jr, Eving CM, Watkins JJ, Isaacs WB. The E-cadherin cell-cell adhesion pathway in urologie malignancies. World J Urol 1995; 13: 364-368.
32. Mialhe A, Louis J, Montlevier S. et al. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors?. Inv Metastasis 1997; 17: 124-137.
33. Mashimo T, Watabe M, Hirota S, et al. The expression of the KAI1 gene, a tumour metastasis suppressor, is directly activated by p53. Proc Nat l Acad Sci U S A 1998; 95: 11307-11311.
34. Momand J, Zambetti GP. MDM-2: 'big brother' of p53. J Cell Biochem 1997; 64: 343-352.
35. Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4: 829-834.
36. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-1094.